deltatrials
Terminated PHASE1 INTERVENTIONAL 3-arm NCT02574910

Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1

A Phase 1 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase Deficiency

Sponsor: Children's Hospital Los Angeles

Interventions Abiraterone acetate
Updated 15 times since 2017 Last updated: Oct 13, 2025 Started: Aug 1, 2017 Primary completion: Jun 3, 2023 Completion: Jun 3, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study has been affected significantly by the COVID pandemic, drug supply/drug amendment, low recruitment interest, and FDA approval of another drug with the same indication, so this study has not met its primary endpoint data requirements.

A PHASE1 clinical study on Congenital Adrenal Hyperplasia, this trial is terminated or withdrawn. The trial is conducted by Children's Hospital Los Angeles and has accumulated 15 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~Apr 2020 · 14 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Mar 2022 · 12 months · monthly snapshot~Mar 2022 – ~Mar 2023 · 12 months · monthly snapshot~Mar 2023 – ~Dec 2023 · 9 months · monthly snapshot~Dec 2023 – ~Apr 2024 · 4 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2025 · 15 months · monthly snapshot~Dec 2025 – present · 8 months · monthly snapshot

Change History

15 versions recorded
  1. Dec 2025 — Present [monthly]

    Terminated PHASE1

    Status: SuspendedTerminated

  2. Sep 2024 — Dec 2025 [monthly]

    Suspended PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Suspended PHASE1

  4. Apr 2024 — Jul 2024 [monthly]

    Suspended PHASE1

    Status: RecruitingSuspended

  5. Dec 2023 — Apr 2024 [monthly]

    Recruiting PHASE1

    Status: Active Not RecruitingRecruiting

Show 10 earlier versions
  1. Mar 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE1

  2. Mar 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE1

  3. Mar 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1

  5. Apr 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

    Status: RecruitingActive Not Recruiting

  6. Feb 2019 — Apr 2020 [monthly]

    Recruiting PHASE1

  7. Jun 2018 — Feb 2019 [monthly]

    Recruiting PHASE1

  8. Aug 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet RecruitingRecruiting

  9. Feb 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE1

  10. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Children's Hospital Los Angeles
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • University of Michigan
  • University of Texas Southwestern Medical Center
Data source: University of Texas Southwestern Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .